Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

fitability for the Company."

2010 and Recent Highlights: XIAFLEX:

  • Worldwide revenues for XIAFLEX were $18.4 million for the year ending December 31, 2010 versus $3.6 million in 2009.
  • Sales of XIAFLEX in the U.S. were $14.1 million in 2010, representing approximately 4,500 vials of XIAFLEX.  The product was launched in late March 2010.
  • Beginning January 1, 2011, a new XIAFLEX-specific J-code (J0775) was available for use in the U.S. to identify XIAFLEX for obtaining reimbursement from Medicare, Medicaid and commercial health plans.
  • On December 16, 2010, Auxilium's EU partner, Pfizer Inc. (Pfizer), received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending European Union (EU) approval for Xiapex (EU tradename for collagenase clostridium histolyticum) as treatment for Dupuytren's contracture in adult patients with a palpable cord.  Pfizer expects EMA approval of Xiapex in the first quarter of 2011.
  • On December 6, 2010, The Journal of Hand Surgery published in its December online edition the Company's pivotal CORD II phase III clinical trial of XIAFLEX. The CORD II study is the second pivotal clinical trial examining the treatment of Dupuytren's contracture with XIAFLEX.
  • On October 12, 2010, the U.S. Patent and Trademark Office issued U.S. Patent No. 7,811,560 covering XIAFLEX with independent claims that recite a drug product, a process for producing the drug product, and pharmaceutical formulations comprising the drug product.  As a result, the Company expects XIAFLEX to have patent protection through 2028.
  • On October 11, 2010, the Company announced that the first subject had been dosed with XIAFLEX in the largest ever global phase III program for the treatment of Peyronie's disease, a devastating disease that is estimated to affect approximately 5% of adult men.(i) Auxilium anticipates completing enrol
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
    11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
    (Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
    (Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
    (Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
    Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
    ... PARK, Md. -- University of Maryland physicists have ... mobility, a measure of how well a material conducts ... room temperature. Graphene, a single-atom-thick sheet of graphite, is ... metals. , Their results, published online in the journal ...
    ... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... announced today that the United States Patent and,Trademark ... Patent No.,5,676,146. The ,146 patent covers mixtures of ... radiopaque material, such as nondemineralized,or partially demineralized bone, ...
    ... research companies invested a record $58.8,billion last year ... and vaccines -- an increase of nearly $3 ... Research and Manufacturers of,America (PhRMA) and Burrill & ... 50th anniversary, which it observes today., This ...
    Cached Biology Technology:UM physicists show electrons can travel over 100 times faster in graphene than in silicon 2UM physicists show electrons can travel over 100 times faster in graphene than in silicon 3U.S. Patent Office Confirms Validity of Osteotech's U.S. Patent No. 5,676,146 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 3
    (Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
    (Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
    (Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
    Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
    ... Stromal Caveolin-1 Predicts Breast Cancer Prognosis Two ... American Journal of Pathology demonstrate the role of ... cancer progression. These articles are highlighted by an ... endocytosis and signal transduction, plays a major role in ...
    ... (22 May 2009)The Global Crop Diversity Trust announced today ... the millions of seed samples maintained in 1,500 crop ... critically needed to protect food production from the ravages ... wide range of innovative projects, including a search in ...
    ... Once placed into a patient,s body, stem cells intended ... wreaking havoc simply because they are no longer under ... has the potential to solve this problem, according to ... Medical Center published in a recent issue of the ...
    Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 3Gene therapy could expand stem cells' promise 2
    ... enables sensitive, fast and specific detection of ... Short hybridisation time ( ... spreads Multiplex capability Available with ... Probes available with different labels. ...
    ... is a K-12 strain ideally suited as ... high transformation efficiency, blue/white screening capability (with ... result in high yields of excellent quality ... is potentially useful as a stringent host ...
    ... kit contains all the reagents required for ... c reductase activity in cell and tissue ... (ER)]. It has been tested on samples ... kidney, brain, spleen, and heart muscle from ...
    ... is an automated, confocal, real-time, single cell ... been integrated into a single, compact unit. ... provide high-resolution, automated confocal imaging with sophisticated ... cell-based assays. The system allows the user ...
    Biology Products: